WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

16.01.2017: AdHoc-Announcement: WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited ....More
16.01.2017: Press release: WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited  ....More

 

 

 

Seite gelesen: 20906 | Heute: 382